Enanta Pharmaceuticals (ENTA) Assets Average (2013 - 2026)

Enanta Pharmaceuticals' Assets Average history runs 14 years deep, the most recent figure standing at $322.1 million for Q1 2026.

• Quarterly Assets Average fell 4.08% year-over-year to $322.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322.1 million (down 4.08% YoY) and the FY2025 annual result came in at $328.7 million, down 21.64% from the prior year.
• Assets Average was $322.1 million for Q1 2026 at Enanta Pharmaceuticals, up from $305.1 million in the prior quarter.
• Across five years, Assets Average topped out at $478.7 million in Q3 2023 and bottomed at $290.9 million in Q3 2025.
• A 5-year average of $375.1 million and a median of $380.3 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average rose 25.88% — and 2025, when it decreased 24.98%.
• Enanta Pharmaceuticals' Assets Average stood at $361.5 million in 2022, then advanced by 23.21% to $445.4 million in 2023, then slipped by 18.58% to $362.6 million in 2024, then decreased by 15.86% to $305.1 million in 2025, then climbed by 5.57% to $322.1 million in 2026.
• Business Quant data shows ENTA's Assets Average at $322.1 million in Q1 2026, $305.1 million in Q4 2025, and $290.9 million in Q3 2025.